Chugai Pharmaceutical Co., Ltd.
4519
Xếp hạng trong cổ phiếu
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Giá cổ phiếu
$41.60
Vốn hóa thị trường
$68.46B
Thay đổi (1 ngày)
0.94%
Thay đổi (1 năm)
-12.56%
Quốc gia
JP
Giao dịch Chugai Pharmaceutical Co., Ltd. (4519)
Danh mục
Healthcare
Lịch sử giá cổ phiếu của Chugai Pharmaceutical Co., Ltd. (4519)
Giá đóng cửa cao nhất: $40.42 vào 2026-10-01
Giá đóng cửa thấp nhất: $4.46 vào 2000-01-01
Giá đóng cửa thấp nhất: $4.46 vào 2000-01-01
Lịch sử giá cổ phiếu của Chugai Pharmaceutical Co., Ltd. từ 2000 đến 2026
Hiệu suất giá cổ phiếu hàng năm
| Năm | Hiệu suất |
|---|---|
| 2026 (TTM) | -3.86% |
| 2025 | 20.02% |
| 2024 | 18.95% |
| 2023 | 41.96% |
| 2022 | -19.72% |
| 2021 | -33.50% |
| 2020 | 61.46% |
| 2019 | 45.44% |
| 2018 | 21.04% |
| 2017 | 84.89% |
| 2016 | -20.55% |
| 2015 | 36.00% |
| 2014 | 14.16% |
| 2013 | 15.12% |
| 2012 | 23.22% |
| 2011 | -11.67% |
| 2010 | -4.50% |
| 2009 | 8.22% |
| 2008 | 9.72% |
| 2007 | -22.24% |
| 2006 | -6.63% |
| 2005 | 39.47% |
| 2004 | 8.20% |
| 2003 | 67.34% |
| 2002 | -27.51% |
| 2001 | -28.51% |
| 2000 | 0.00% |
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
| Công ty | Giá cổ phiếu | Thay đổi 1năm% | Quốc gia |
|---|---|---|---|
| $1.31K | 61.09% |
US
|
|
| $268.73 | 39.28% |
US
|
|
| $284.43 | 24.38% |
US
|
|
| $148.42 | 69.41% |
US
|
|
| $482.01 | 30.76% |
CH
|
